Paul C. Brown

An FDA/CDER perspective on nonclinical testing strategies: Classical toxicology approaches and new approach methodologies (NAMs)

Amy M. Avila, Ilona Bebenek, Jessica A. Bonzo et al. · Regulatory Toxicology and Pharmacology · 2020 · 183 citations

Pharmacy, Toxicology, Analytical Toxicology +14

Gaps and challenges in nonclinical assessments of pharmaceuticals: An FDA/CDER perspective on considerations for development of new approach methodologies

Amy M. Avila, Ilona Bebenek, Donna L. Mendrick et al. · Regulatory Toxicology and Pharmacology · 2023 · 45 citations

Pharmacy, Pharmacology, Drug Approval Processes +11

Opportunities for use of one species for longer-term toxicology testing during drug development: A cross-industry evaluation

Helen Prior, Paul Baldrick, Sonja Beken et al. · Regulatory Toxicology and Pharmacology · 2020 · 40 citations · Full text

Pharmacy, Pharmacology, Toxicology +16

Recommendations from a global cross-company data sharing initiative on the incorporation of recovery phase animals in safety assessment studies to support first-in-human clinical trials

Fiona Sewell, Kathryn Chapman, Paul Baldrick et al. · Regulatory Toxicology and Pharmacology · 2014 · 34 citations · Full text

Pharmacy, Pharmacology, Toxicology +15

Advancing alternative methods to reduce animal testing

Chad P. Nelson, Paul C. Brown, Suzanne Fitzpatrick et al. · Science · 2024 · 28 citations · Full text

Agriculture, Animal Sciences, Animal Welfare +8